Toxic aldehyde related diseases and treatment
AssigneeAldeyra Therapeutics, Inc.
InventorsTodd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
Life of this patent
Estimating the term…
Abstract
The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
Claims23
1-49. (canceled)
A method of treating ocular rosacea with or without meibomian gland dysfunction, comprising administering to a subject with ocular rosacea with or without meibomian gland dysfunction, a therapeutically effective amount a compound, wherein the compound is:
- or a pharmaceutically acceptable salt thereof.
(canceled)
(canceled)
69, The method of claim 68, wherein the compound is present at a concentration of about 0.09% -0.5% w/v.
The method of claim 69, wherein the sulfobutylether-β-cyclodextrin is present at a concentration of about 9.5% w/v.
Dependencies are inferred from the claim text.